Yash Pharma Laboratories Pvt Ltd.

Jagsonpal Pharmaceuticals Ltd. has signed a Business Transfer Agreement for the acquisition of India and Bhutan business of Yash Pharma for INR 92.47 Crores. The consideration would be paid in cash and would be paid from internal accruals. The Company had a cash balance of INR 135 crores as on December 31, 2023. The transaction is subject to customary closing conditions and is expected to close within 45 days. The acquisition gives access to ~INR 20,000 Crores market of Dermatology and Childcare segment and aligns well with the company’s strategic goal to broaden its presence in the Indian pharmaceutical market. By offering a comprehensive range of products, the aim is to deliver greater value to stakeholders. It strengthens its presence in Western and Eastern regions of the country and gives access to a wider section of specialists – Dermatologists and Paediatricians. Operating since 1972, Yash Pharma is engaged in manufacturing and marketing of Dermatology and Childcare focused products. The company has a nation-wide field presence of ~ 225 people and a portfolio of 33 brands comprising Demelanizing agents, Antifungals, Haircare, Amoebicidal and Cough preparations. Commenting on the acquisition, Manish Gupta, Managing Director, Jagsonpal Pharmaceuticals stated “The acquisition of the India and Bhutan businesses of Yash Pharma aligns with our vision of becoming a stronger India-focussed healthcare business with multiple growth levers. As part of the transaction, Company gets access to 30+ brands with 4 brands amongst top-10 of their molecule category. This acquisition is a gateway to attractive, fast-growing Dermatology and Childcare segments, bolstering our presence in the Indian pharmaceutical market. We wholeheartedly welcome ~250 Yash Pharma employees to the growing Jagsonpal family. We will now focus on supporting the commercial leadership team to accelerate growth in business as well as leverage synergies.” Growthally Advisors were the advisors for the transaction. ThinkLaw Advocates were the legal advisor while Deloitte Touche Tohmatsu India LLP was the financial diligence partner for Jagsonpal Pharmaceuticals Ltd. Khaitan & Co. were the legal advisor for Yash Pharma.

Jagsonpal to acquire India & Bhutan business of Yash Pharma > April 2024 > May 16, 2024 ## 01 ## Insight into ## Jagsonpal About Jagsonpal Legacy of 6 decades With a solid foundation since 1964, boasting a remarkable 60-year track record Leadership Among Top-10 Companies operating in the Gynaecology segment > 01 Focus Segments Portfolio of specialized products targeted towards Gynaecology & Orthopedics Extensive Coverage Comprehensive reach to ~1.25 lakhs pharmacies across the country > YEARS > 02 | Jagsonpal Pharmaceuticals Ltd. Promoter group Infinity Holdings acquired a majority stake and is now a joint promoter, shaping a stronger path forward About Jagsonpal 01 # Sales Team # Expanse # 1,00,000+ Doctors prescribe Jagsonpal’s products # 750+ Field force executives with specialized product experience # 17 Strong network of stocking points 03 | Jagsonpal Pharmaceuticals Ltd. Journey in last 18 months > 01 Leveraged strategic development of Dydrogesterone to create strong franchise – Divatrone, awarded 1st Runner Up in “New Introductions by Companies up to 500 Cr” in AWACS Marketing Awards 2022 Streamlined operations leading to improved operating margins, expanded by 680 bps in FY23 Created headroom for growth and new launches through divisionalization of main division – One for Gynae and another for Ortho Built-up war-chest for inorganic initiatives through operational levers – generated ₹73 crores of free cash net of dividend and tax since March 22. Cash balance ₹135+ crores on December 31, 2023 04 | Jagsonpal Pharmaceuticals Ltd. About ## Yash Pharma Established in 1972, headquartered in Mumbai ## Yash Pharma Biz: A strategic fit Primary focus on derma and child health segments Nationwide presence, with strengths in eastern and western zones, contributing ~67% to sales Portfolio of 33 brands, with top 10 accounting for ~70% of business > 06 | Jagsonpal Pharmaceuticals Ltd. FY24 Revenue ₹ 47.7 Crores Reach Field force of 225+ individuals, with strength in Eastern and Western parts of the country Prescription-driven Strong base of ~54,000 prescribers Strong presence Deep reach in key states of Maharashtra, Uttar Pradesh, Bihar, Karnataka, and West Bengal Profitable Limited NLEM* Exposure: 4 SKUs, ~11% of sales > 02 > 07 | Jagsonpal Pharmaceuticals Ltd. *National List of Essential Medicines 08 | Jagsonpal Pharmaceuticals Ltd. Four brands feature among Top-10 brands in respective segments Eukroma Itratop Ventiphylline - PD PRU KTC Lulyera Tinilox 18 13 10 9 8 8 8 Brands *MAT Feb’24 Sales (₹ Cr) Segment *Market Share Derma 4.0% 1.3% 8.1% 4.0% 1.6% 2.0% 57.6% > 02 Derma Pedia Derma Derma Derma Pedia *Source: IQVIA *Rank 7 17 2 3 13 15 1Strategic ## Rationale 10 | Jagsonpal Pharmaceuticals Ltd. Company performance (Source: IQVIA) ₹122 Crores, 4 -year CAGR at 7.8% (in-line with CVM) Market opportunity Access to a large market size of ~₹20,000 Crore Doctor specialty Access to wider section of specialists – Dermatologists and Pediatricians Business strength Sales divisions with a field strength of ~225 individuals Fortifies National presence Complimentary strength in Western & Eastern regions of the country Doctor coverage Total doctor reach of ~54,000 prescribers ## Complimentary business with no overlap > 03 44% 19% 21% 15% 11 | Jagsonpal Pharmaceuticals Ltd. ## Strengthens field presence in the Eastern and ## Western regions of the country Sales Divisions Speciality Field Strength Jagsonpal Gynaecology & Orthopaedics 750 Yash Pharma Dermatology & Paediatric 225 Overall 975 NORTH 03 North East West South 49% 18% 17% 16% 27% 23% 38% 12% 12 | Jagsonpal Pharmaceuticals Ltd. ## Enhancing doctor reach Prescriber Speciality Jagsonpal Yash Pharma Overall Gynaecologist   Orthopaedics   General Practitioner    Dermatologist   Paediatrician   Jagsonpal Yash Pharma Overall Prescribers (‘000) 100+ 54+ 150+ 03 Charting ## the future 14 | Jagsonpal Pharmaceuticals Ltd. New segment Provides an opportunity to enter the niche high-value derma-cosmeceutical segment ## Merger and Acquisition levers Cost synergies Extract synergies across all supply chain cost levers Enhanced profitability Operating margins of consolidated business to be >20% in 18 months Sales force Effectiveness Improved field force productivity through resource enhancement > 04 15 | Jagsonpal Pharmaceuticals Ltd. Company ranking Improved rank to 73 rd from 91 st currently by 18 positions Market opportunity Access to a larger market size of ~₹29,000 Crore Doctor specialty Access to wider section of specialist - Gynecologist, Orthopedics, Dermatologist and Pediatricians Business strength Four sales divisions with field strength of ~975 individuals National coverage Strong presence in Northern, Western & Eastern regions Doctor coverage Total doctor list reaches to ~1,54,000 > 04 ## Unlocking opportunities with complementary synergies and strengths Leverage JPL’s strong presence in North & Yash’s depth in West . Field presence in Top-2 metros i.e. Delhi & Mumbai Multiple mid-sized brands , with headroom for growth Specialty expansion to cater to underpenetrated ENT specialists ## Opportunities going ahead Launch products in untapped Derma markets such as Atopic Dermatitis, Acne, etc With surplus cash, continue exploring bolt-on opportunities Align profitability with Jagsonpal within 18 months via supply chain synergies > 04 ## Thank You Registered Office T-210 J, Shahpur Jat New Delhi - 110049 Corporate Office Nimai Tower, 3 rd Floor, Plot No: 412415, Phase – IV, Udyog Vihar, Gurugram, Haryana - 122015 Tel. : 0124-4406710 E-mail : cs@jagsonpal.com Website : www.jagsonpal.com CIN: L74899DL1978PLC009181